Off the Charts

In the "Off The Charts" segment, Cramer went head to head with colleague Carolyn Boroden over the chart of Apple ( AAPL), an Action Alerts PLUS holding, to see if the recent rally in the stock is indeed for real.

Using a weekly chart of Apple, Boroden noted a total of five Fibonacci ratios in the stock, all pointing to its bottom in April. In fact, the Fibonacci ratios on Apple's daily chart also predicted the bottom in the stock within a few days of when it actually occurred. She concluded that based on her research, Apple is poised for a major trend reversal.

Using more traditional technical analysis, Cramer noted that Apple's double bottom has created a strong floor of support for the stock and its recently crossed over its five-day, 13-day, 30-day and, most recently, its 200-day moving averages, all very bullish signs.

How high can Apple go? Boroden saw $582 a share as a shorter-term target, noting that it could approach it's all-time high of $792 a share thereafter.

Cramer said he's not expecting $792 anytime soon, but he does remain bullish on the stock, as it still trades at less than 12 times earnings and has a lot of exposure to the strength building in Europe.

Lightning Round

In the Lightning Round, Cramer was bullish on Rite Aid ( RAD), CVS Caremark ( CVS), Walgreen ( WAG), Standard Motor Products ( SMP) and Lockheed Martin ( LMT).

Cramer was bearish on Lorillard ( LO)

Executive Decision: Daniel Junius

In the "Executive Decision" segment, Cramer sat down with Daniel Junius, president and CEO of the speculative biotech firm ImmunoGen ( IMGN), a stock that's soared 36% since Cramer first got behind it in December 2012 and 18% since he last spoke with Junius in late February.

Junius provided an update on his company's great cancer drug, Kadcyla, which received approval in February. He said the drug has been performing very well and the company's partners are excited about its prospects. Kadcyla is only getting started, Junius noted, and sales in Europe have yet to begin and other indications for the drug are possible.

Junius also responded to recent negative comments surrounding ImmunoGen's four other compounds under development, and in particular concerns over their toxicity in patients. He explained that as part of drug development, dosages are increased to determine at what level they are intolerable to patients, and then the dosages are dialed back to acceptable levels. ImmunoGen's new drugs are no more toxic than anything else on the market, he noted, and, in fact, they're far better.

When asked about the company's cash reserves, Junius said ImmunoGen has plenty of cash for development but may consider more when their drugs are reaching the approval process. By then, however, there will be a lot more data on what those drugs are capable of doing, so finding additional funding will likely not be a problem.

Cramer said he felt the negativity surrounding ImmunoGen was unwarranted given its many successes thus far.

Am I Diversified?

In the "Am I Diversified?" segment, Cramer spoke with callers and responded to tweets sent via Twitter to @JimCramer to see if investors' portfolios have what it takes for today's markets.

The first portfolio included: Johnson & Johnson ( JNJ), Walt Disney ( DIS), Micron Technologies ( MU), Ford ( F) and Xerox ( XRX).

Cramer said that Micron and Xerox were both technology stocks and he'd sell Xerox and add a defense stock in order to be properly diversified.

The second portfolio's top holdings included: Apple, BP ( BP), Carlyle Group ( CG), Duke Energy ( DUK) and AT&T ( T).

Cramer said this portfolio was perfectly diversified.

To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.

-- Written by Scott Rutt in Washington, D.C.

To email Scott about this article, click here: Scott Rutt

Follow Scott on Twitter @ScottRutt or get updates on Facebook, ScottRuttDC
At the time of publication, Cramer's Action Alerts PLUS had a position in AAPL, F and JPM.

Jim Cramer, host of the CNBC television program "Mad Money," is a Markets Commentator for, Inc., and CNBC, and a director and co-founder of All opinions expressed by Mr. Cramer on "Mad Money" are his own and do not reflect the opinions of or its affiliates, or CNBC, NBC Universal or their parent company or affiliates. Mr. Cramer's opinions are based upon information he considers to be reliable, but neither, nor CNBC, nor either of their affiliates and/or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such. Mr. Cramer's statements are based on his opinions at the time statements are made, and are subject to change without notice. No part of Mr. Cramer's compensation from CNBC or is related to the specific opinions expressed by him on "Mad Money."

None of the information contained in "Mad Money" constitutes a recommendation by Mr. Cramer, or CNBC that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the program. Mr. Cramer's past results are not necessarily indicative of future performance. Neither Mr. Cramer, nor, nor CNBC guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the program. The strategy or investments discussed may fluctuate in price or value and you may get back less than you invested. Before acting on any information contained in the program, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.

Some of the stocks mentioned by Mr. Cramer on "Mad Money" are held in Mr. Cramer's Action Alerts PLUS Portfolio. When that is the case, appropriate disclosure is made on the program and in the "Mad Money" recap available on The Action Alerts PLUS Portfolio contains all of Mr. Cramer's personal investments in publicly-traded equity securities only, and does not include any mutual fund holdings or other institutionally managed assets, private equity investments, or his holdings in, Inc. Since March 2005, the Action Alerts PLUS Portfolio has been held by a Trust, the realized profits from which have been pledged to charity. Mr. Cramer retains full investment discretion with respect to all securities contained in the Trust. Mr. Cramer is subject to certain trading restrictions, and must hold all securities in the Action Alerts PLUS Portfolio for at least one month, and is not permitted to buy or sell any security he has spoken about on television or on his radio program for five days following the broadcast.

If you liked this article you might like

Watch Out For the Dominoes That Fall: Cramer's 'Mad Money' Recap (Wed 9/20/17)

This Is How to Avoid Becoming Amazon Roadkill

Cramer: Dominoes Are in Play Today

Analyst Rips Ralph Lauren Stock, Right After Glitzy Fashion Show

Walmart Upping Current Worker Hours Instead of Hiring for the Holidays